清华-杨森传染病研究中心成立 启动公共健康日
2011-4-21 9:37:36 (生物谷Bioon.com)
值清华百年校庆之际，清华大学医学院与西安杨森制药有限公司强强联手，成立清华-杨森传染病联合研究中心。“清华-杨森公共健康日”也于今日正式启动，结核病和艾滋病是今年的研究方向。
据了解，新成立的传染病联合研究中心汇集了清华大学医学院、生命科学学院和公共健康研究中心等学院中甄选出来的有经验的研究者，以及杨森公司多位长期从事传染病药物研发的科学家和高层管理人员。双方优势资源互补，旨在加强传染病领域的基础研究，为患者提供高效且可承受的药物，以满足中国患者的需求。
目前，艾滋病和结核病是中国每年死亡人数最多的两大传染病。根据卫生部统计，中国是名副其实的“结核大国”，现有结核病患者500万，结核病菌感染者估计有5亿人之多，占中国总人口的45%。同时，艾滋病在中国虽然得到控制，但疫情仍呈上升趋势，中国目前存活的艾滋病感染者和病人有74万。而艾滋病患者一旦感染上结核病菌，80%的艾滋病人会马上发病，30%-40%的艾滋病患者会最终死于肺结核。
今天正式启动的清华-杨森公共健康日，正是要致力于唤起全社会对传染病严峻形势的认识，并增强公众对传染病的防范意识。2011年的公共健康日的研究方向是结核病和艾滋病，这也是刚刚成产的传染病联合研究中心主要课题之一。
西安杨森制药有限公司总裁何赛德认为，遏制结核病和艾滋病蔓延必须“防”、“治”结合，这也是为什么此次清华大学和杨森公司合作，在成立传染病联合研究中心的同时，启动清华-杨森公共健康日的初衷。
“可怕的不仅仅是传染病本身，公众对传染病缺乏正确认识才是防控传染病的最大障碍之一。”卫生部病症预防控制局副局长郝阳在出席今天的公共健康日活动时说，“清华大学和杨森公司的合作，是建立创新型的‘产-学-研-用’合作机制的一次有益实践。”
清华大学生命科学学院院长、医学院常务副院长施一公说，清华和杨森是真正的强强联合，今后会有更多世界一流的传染病领域的专家加入进来，并且依托于强生优势加强药物转化研究，真正造福于中国百姓，为中国老百姓带来福音。
在当天下午举行的传染病最新进展专题论坛上，专家学者就艾滋病药物的发现与发展、而多工结核病的诊治及在中国的现状等主题进行了演讲。(生物谷Bioon.com)
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2010年12月即将出版的《中国特色医疗金鉴》登载的刘君主任及其机构 |
| |
|
|
Tsinghua University - Research Center Yeung Sum of infectious diseases of public health at start
2011-4-21 9:37:36 (Bio Valley Bioon.com)
Value of the centennial celebration of the occasion of Tsinghua University, Tsinghua University School of Medicine and Xian-Janssen Pharmaceutical Co., Ltd. joined forces, the establishment of Tsinghua University - Joint Research Centre of Infectious Diseases Yeung Sum. "Tsinghua University - Yeung Sum of Public Health Day" is officially launched today, tuberculosis and AIDS research this year.
It is understood that the newly established Joint Research Centre of Infectious Diseases, Tsinghua University School of Medicine brings together the School of Life Sciences and Public Health Research Institute in the selection of out of experienced researchers, as well as a number of Yeung Sum companies engaged in drug research and development of infectious diseases scientists and senior management. Two advantages of complementary resources, to strengthen basic research in the field of infectious diseases, providing patients with effective and affordable drugs to meet the needs of Chinese patients.
Currently, AIDS and TB is the number of deaths in China each year up to the two diseases. According to Health Ministry statistics, China is a true "end nuclear power", the existing 500 million TB patients, TB infection who estimated as many as 5 million people, accounting for 45% of the total population. Meanwhile, AIDS in China, although under control, but still on an upward trend of the epidemic, China has the survival of patients with AIDS and 74 million. Once infected with the AIDS TB bacteria, 80% of the AIDS disease immediately, 30% -40% of AIDS patients eventually died of tuberculosis.
Tsinghua University today officially launched - Yeung Sum of Public Health Day, it is to be committed to arouse the whole society's awareness of the grim situation of infectious diseases, and increase public awareness of prevention of infectious diseases. Public Health Day 2011, the research direction of TB and AIDS, which is produced just as the main subject of infectious disease one of the Joint Research Centre.
Xian-Janssen Pharmaceutical Co., Ltd. He Said that the President, to curb the spread of TB and AIDS must be "anti", "rule" binding, which is why the Tsinghua University and Dr YEUNG Sum companies in setting up the Joint Research Centre of infectious diseases at the same time, start Tsinghua University - Yeung Sum Public Health Day in mind.
"Terrible is not only infectious disease itself, the lack of a correct understanding of the public on communicable diseases prevention and control of infectious diseases is one of the biggest obstacles." The Ministry of Health Disease Control and Prevention, Hao Yang, Deputy Secretary for Public Health in attendance at today's events said, "Tsinghua University and Dr YEUNG Sum's cooperation, is to establish innovative 'products - learning - research - with' a good practice of cooperation mechanism."
Dean of the School of Life Sciences, Tsinghua University, School of Medicine, said Shi Yigong executive vice president, Tsinghua University and is a real combination Yeung Sum, the future will have more areas of the world's leading infectious disease experts to join in, and relying on the advantage of Johnson & Johnson enhance drug transformation, the real benefit the Chinese people, to bring the Gospel to the Chinese people.
Infectious diseases in the afternoon at the latest forum topics, experts and scholars to the discovery and development of AIDS drugs, while TB treatment and the multiplexed status in China, such as a speech topic. (Bio Valley Bioon.com)
|
